[Hormonal replacement therapy in patients with cervical and ovarian cancers].
Hormonal replacement therapy in women following primary treatment for squamous cell carcinoma of the cervix uteri is harmless. In case of adenocarcinoma of the cervix, guidelines for hormonal replacement therapy according to those valid for endometrial cancer are recommended. In women treated for ovarian cancer, a combined cyclic or continuous estrogen/gestagen substitution - the latter also in hysterectomized women - is to be favored. Signs of androgen deficiency are to be respected. Short-term clinical, sonographical, and biochemical control investigations are recommended.
Urdl
W
W
Klinische Abteilung für Gynäkologische Endokrinologie und Fortpflanzungs- medizin, Geburtshilflich-gynäkologische Universitätsklinik Graz, Osterreich.
D000230:Adenocarcinoma / Q000139:chemically induced / Q000534:rehabilitation*; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced / Q000534:rehabilitation*; D003131:Combined Modality Therapy; D000075202:Contraindications; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D007044:Hysterectomy; D010051:Ovarian Neoplasms / Q000139:chemically induced / Q000534:rehabilitation*; D011372:Progestins / Q000008:administration & dosage; D012307:Risk Factors; D002583:Uterine Cervical Neoplasms / Q000139:chemically induced / Q000534:rehabilitation*
D011372:Progestins